The future of inflammatory bowel disease management: combining progress in trial design with advances in targeted therapy.

Journal article

Anti-tumour necrosis factor antagonists have appreciably improved patient outcomes in Crohn's disease, shifting the goals of treatment from control of symptoms to clinical remission (Crohn's disease activity index <150) combined with mucosal healing - the new concept of 'deep remission'. Achieving deep remission brings clinically meaningful benefits, including reduced hospitalization and reduced need for surgery. Aspects such as the dose, timing and intensification of anti-tumour necrosis ...

Expand abstract

Authors: Travis, S; Feagan, BG; Rutgeerts, P; van Deventer, S

• Publication status: Published
• Journal: Journal of Crohn's and colitis
• Volume: 6 Suppl 2
• Pages: S250-S259
• Publication date: 2012-02-01
• DOI: 10.1016/s1873-9946(12)60505-4
• EISSN: 1876-4479
• ISSN: 1873-9946
• Language: English
• Keywords: Humans; Antibodies, Monoclonal; Inflammatory Bowel Diseases; Research Design; Anti-Inflammatory Agents; Crohn Disease; Induction Chemotherapy; Randomized Controlled Trials as Topic; Tumor Necrosis Factor-alpha; Molecular Targeted Therapy